Palbociclib
Description
Name: Palbociclib
Type: small molecule
Groups: approved
Indication: Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Accession Number: DB09073 ( DB09073)
Description: Palbociclib is an oral, reversible, selective, small-molecule inhibitor of CDK4 and CDK6 indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. CDK4 and CDK6 along with their regulatory partner cyclin D1 play a key role in regulating the G1- to S-phase cell-cycle transition via regulation of phosphorylation of the retinoblastoma (Rb) protein. Inhibition of these proteins leads to reduced phosphorylation of Rb, inhibition of downstream signalling, and increased tumor growth arrest. Palbociclib received an accelerated approval from the Food and Drug Administration on February 3, 2015.
Structure:
Prescription Products:
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
Prescription Products:
International Brands
Brand Names
Brand Mixtures
Categories
Type: small molecule
Groups: approved
Indication: Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Accession Number: DB09073 ( DB09073)
Description: Palbociclib is an oral, reversible, selective, small-molecule inhibitor of CDK4 and CDK6 indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. CDK4 and CDK6 along with their regulatory partner cyclin D1 play a key role in regulating the G1- to S-phase cell-cycle transition via regulation of phosphorylation of the retinoblastoma (Rb) protein. Inhibition of these proteins leads to reduced phosphorylation of Rb, inhibition of downstream signalling, and increased tumor growth arrest. Palbociclib received an accelerated approval from the Food and Drug Administration on February 3, 2015.
Structure:
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Ibrance | capsule | 125 mg/1 | oral | 03-02-2015 | US | |
| Ibrance | capsule | 75 mg/1 | oral | 03-02-2015 | US | |
| Ibrance | capsule | 100 mg/1 | oral | 03-02-2015 | US | |
| Ibrance | capsule | 125 mg/1 | oral | 03-02-2015 | US |
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Ibrance | capsule | 125 mg/1 | oral | 03-02-2015 | US | |
| Ibrance | capsule | 75 mg/1 | oral | 03-02-2015 | US | |
| Ibrance | capsule | 100 mg/1 | oral | 03-02-2015 | US | |
| Ibrance | capsule | 125 mg/1 | oral | 03-02-2015 | US |
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
| Brand Name | Ingredients |
|---|---|
| Ibrance | Palbociclib |
| Ibrance | Palbociclib |
| Ibrance | Palbociclib |
| Ibrance | Palbociclib |
| Brand Name | Ingredients |
|---|---|
| Ibrance | Palbociclib |
| Ibrance | Palbociclib |
| Ibrance | Palbociclib |
| Ibrance | Palbociclib |
Categories
- No Category
Pharmacology
Indication: Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Pharmacodynamics: Not Available
Mechanism of action: Palbociclib is an oral, reversible, selective, small-molecule inhibitor of CDK4 and CDK6. CDK4 and CDK6 along with their regulatory partner cyclin D1 play a key role in regulating the G1- to S-phase cell-cycle transition via regulation of phosphorylation of the retinoblastoma (Rb) protein.
Absorption: The mean Cmax of palbociclib is generally observed between 6 to 12 hours (time to reach maximum concentration, Tmax) following oral administration. The mean absolute bioavailability after an oral 125 mg dose is 46%.
Volume of distribution:
Protein binding: Binding of palbociclib to human plasma proteins in vitro is approximately 85%.
Metabolism: Not Available
Route of elimination: Palbociclib was extensively metabolized with unchanged drug accounting for 2.3% and 6.9% of radioactivity in feces and urine, respectively. In feces, the sulfamic acid conjugate of palbociclib was the major drug-related component, accounting for 26% of the administered dose.
Half life: The mean plasma elimination half-life is 29 hours.
Clearance: Not Available
Toxicity: Not Available
Affected organisms
SNP Mediated Adverse Drug Reactions
Pharmacodynamics: Not Available
Mechanism of action: Palbociclib is an oral, reversible, selective, small-molecule inhibitor of CDK4 and CDK6. CDK4 and CDK6 along with their regulatory partner cyclin D1 play a key role in regulating the G1- to S-phase cell-cycle transition via regulation of phosphorylation of the retinoblastoma (Rb) protein.
Absorption: The mean Cmax of palbociclib is generally observed between 6 to 12 hours (time to reach maximum concentration, Tmax) following oral administration. The mean absolute bioavailability after an oral 125 mg dose is 46%.
Volume of distribution:
- The mean apparent distribution of palbociclib is 2583 L, suggesting that palbociclib penetrates extensively into peripheral tissues.
Protein binding: Binding of palbociclib to human plasma proteins in vitro is approximately 85%.
Metabolism: Not Available
Route of elimination: Palbociclib was extensively metabolized with unchanged drug accounting for 2.3% and 6.9% of radioactivity in feces and urine, respectively. In feces, the sulfamic acid conjugate of palbociclib was the major drug-related component, accounting for 26% of the administered dose.
Half life: The mean plasma elimination half-life is 29 hours.
Clearance: Not Available
Toxicity: Not Available
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
Manufacturers:
Packagers:
Dosage forms
Prices
Patents
- Not Available
Packagers:
- Not Available
Dosage forms
| Form | Route | Strength |
|---|---|---|
| Capsule | oral | 100 mg/1 |
| Capsule | oral | 125 mg/1 |
| Capsule | oral | 75 mg/1 |
| Form | Route | Strength |
|---|---|---|
| Capsule | oral | 100 mg/1 |
| Capsule | oral | 125 mg/1 |
| Capsule | oral | 75 mg/1 |
Prices
| Unit description | Cost | Unit |
|---|
| Unit description | Cost | Unit |
|---|
Patents
| Country | Patent Number | Approved | Expires (estimated) |
|---|---|---|---|
| 6936612 | United States | 2003-01-16 | 2023-01-22 |
| 7208489 | United States | 2005-01-28 | 2023-01-16 |
| 7456168 | United States | 2007-04-11 | 2023-01-16 |
Interactions
Drug Interactions
Food Interactions:
| Drug | Interaction |
|---|---|
| ado-trastuzumab emtansine | The serum concentration of ado-trastuzumab emtansine can be increased when it is combined with Palbociclib. |
| Alfentanil | The serum concentration of Alfentanil can be increased when it is combined with Palbociclib. |
| Alfuzosin | The serum concentration of Alfuzosin can be increased when it is combined with Palbociclib. |
| Alitretinoin | The serum concentration of Alitretinoin can be increased when it is combined with Palbociclib. |
| Alprazolam | The serum concentration of Alprazolam can be increased when it is combined with Palbociclib. |
| Aminophylline | The serum concentration of Aminophylline can be increased when it is combined with Palbociclib. |
| Amiodarone | The serum concentration of Amiodarone can be increased when it is combined with Palbociclib. |
| Amlodipine | The serum concentration of Amlodipine can be increased when it is combined with Palbociclib. |
| Aprepitant | The serum concentration of Aprepitant can be increased when it is combined with Palbociclib. |
| Aripiprazole | The serum concentration of Aripiprazole can be increased when it is combined with Palbociclib. |
| Armodafinil | The serum concentration of Armodafinil can be increased when it is combined with Palbociclib. |
| Atazanavir | The serum concentration of Palbociclib can be increased when it is combined with Atazanavir. |
| Atorvastatin | The serum concentration of Atorvastatin can be increased when it is combined with Palbociclib. |
| Avanafil | The serum concentration of Avanafil can be increased when it is combined with Palbociclib. |
| Axitinib | The serum concentration of Axitinib can be increased when it is combined with Palbociclib. |
| Benzphetamine | The serum concentration of Benzphetamine can be increased when it is combined with Palbociclib. |
| Bexarotene | The serum concentration of Palbociclib can be decreased when it is combined with Bexarotene. |
| Bisoprolol | The serum concentration of Bisoprolol can be increased when it is combined with Palbociclib. |
| Boceprevir | The serum concentration of Palbociclib can be increased when it is combined with Boceprevir. |
| Bosentan | The serum concentration of Palbociclib can be decreased when it is combined with Bosentan. |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Palbociclib. |
| Brexpiprazole | The serum concentration of Brexpiprazole can be increased when it is combined with Palbociclib. |
| Bromocriptine | The serum concentration of Bromocriptine can be increased when it is combined with Palbociclib. |
| Budesonide | The serum concentration of Budesonide can be increased when it is combined with Palbociclib. |
| Buprenorphine | The serum concentration of Buprenorphine can be increased when it is combined with Palbociclib. |
| Buspirone | The serum concentration of Buspirone can be increased when it is combined with Palbociclib. |
| Cabazitaxel | The serum concentration of Cabazitaxel can be increased when it is combined with Palbociclib. |
| Cabozantinib | The serum concentration of Cabozantinib can be increased when it is combined with Palbociclib. |
| Calcitriol | The serum concentration of Calcitriol can be increased when it is combined with Palbociclib. |
| Carbamazepine | The serum concentration of Palbociclib can be decreased when it is combined with Carbamazepine. |
| Ceritinib | The serum concentration of Palbociclib can be increased when it is combined with Ceritinib. |
| Chlordiazepoxide | The serum concentration of Chlordiazepoxide can be increased when it is combined with Palbociclib. |
| Chloroquine | The serum concentration of Chloroquine can be increased when it is combined with Palbociclib. |
| Cilostazol | The serum concentration of Cilostazol can be increased when it is combined with Palbociclib. |
| Cinacalcet | The serum concentration of Cinacalcet can be increased when it is combined with Palbociclib. |
| Cisapride | The serum concentration of Cisapride can be increased when it is combined with Palbociclib. |
| Citalopram | The serum concentration of Citalopram can be increased when it is combined with Palbociclib. |
| Clarithromycin | The serum concentration of Palbociclib can be increased when it is combined with Clarithromycin. |
| Clonazepam | The serum concentration of Clonazepam can be increased when it is combined with Palbociclib. |
| Clorazepate | The serum concentration of Clorazepate can be increased when it is combined with Palbociclib. |
| Clozapine | The risk or severity of adverse effects can be increased when Palbociclib is combined with Clozapine. |
| Cobicistat | The serum concentration of Palbociclib can be increased when it is combined with Cobicistat. |
| Cobimetinib | The serum concentration of Cobimetinib can be increased when it is combined with Palbociclib. |
| Cocaine | The serum concentration of Cocaine can be increased when it is combined with Palbociclib. |
| Colchicine | The serum concentration of Colchicine can be increased when it is combined with Palbociclib. |
| Conivaptan | The serum concentration of Palbociclib can be increased when it is combined with Conivaptan. |
| Crizotinib | The serum concentration of Crizotinib can be increased when it is combined with Palbociclib. |
| Cyclosporine | The serum concentration of Cyclosporine can be increased when it is combined with Palbociclib. |
| Cyproterone acetate | The serum concentration of Cyproterone acetate can be increased when it is combined with Palbociclib. |
| Dabrafenib | The serum concentration of Palbociclib can be decreased when it is combined with Dabrafenib. |
| Daclatasvir | The serum concentration of Daclatasvir can be increased when it is combined with Palbociclib. |
| Dantrolene | The serum concentration of Dantrolene can be increased when it is combined with Palbociclib. |
| Dapsone | The serum concentration of Dapsone can be increased when it is combined with Palbociclib. |
| Darifenacin | The serum concentration of Darifenacin can be increased when it is combined with Palbociclib. |
| Darunavir | The serum concentration of Palbociclib can be increased when it is combined with Darunavir. |
| Dasatinib | The serum concentration of Dasatinib can be increased when it is combined with Palbociclib. |
| Deferasirox | The serum concentration of Palbociclib can be decreased when it is combined with Deferasirox. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Palbociclib. |
| Dexamethasone | The serum concentration of Palbociclib can be decreased when it is combined with Dexamethasone. |
| Diazepam | The serum concentration of Diazepam can be increased when it is combined with Palbociclib. |
| Dihydroergotamine | The serum concentration of Dihydroergotamine can be increased when it is combined with Palbociclib. |
| Diltiazem | The serum concentration of Diltiazem can be increased when it is combined with Palbociclib. |
| Disopyramide | The serum concentration of Disopyramide can be increased when it is combined with Palbociclib. |
| Docetaxel | The serum concentration of Docetaxel can be increased when it is combined with Palbociclib. |
| Dofetilide | The serum concentration of Dofetilide can be increased when it is combined with Palbociclib. |
| Domperidone | The serum concentration of Domperidone can be increased when it is combined with Palbociclib. |
| Doxazosin | The serum concentration of Doxazosin can be increased when it is combined with Palbociclib. |
| Doxorubicin | The serum concentration of Doxorubicin can be increased when it is combined with Palbociclib. |
| Dronedarone | The serum concentration of Dronedarone can be increased when it is combined with Palbociclib. |
| Efavirenz | The serum concentration of Palbociclib can be decreased when it is combined with Efavirenz. |
| Eletriptan | The serum concentration of Eletriptan can be increased when it is combined with Palbociclib. |
| Eliglustat | The serum concentration of Eliglustat can be increased when it is combined with Palbociclib. |
| Enzalutamide | The serum concentration of Palbociclib can be decreased when it is combined with Enzalutamide. |
| Eplerenone | The serum concentration of Eplerenone can be increased when it is combined with Palbociclib. |
| Ergoloid mesylate | The serum concentration of Ergoloid mesylate can be increased when it is combined with Palbociclib. |
| Ergonovine | The serum concentration of Ergonovine can be increased when it is combined with Palbociclib. |
| Ergotamine | The serum concentration of Ergotamine can be increased when it is combined with Palbociclib. |
| Erlotinib | The serum concentration of Erlotinib can be increased when it is combined with Palbociclib. |
| Erythromycin | The serum concentration of Erythromycin can be increased when it is combined with Palbociclib. |
| Escitalopram | The serum concentration of Escitalopram can be increased when it is combined with Palbociclib. |
| Eslicarbazepine acetate | The serum concentration of Palbociclib can be decreased when it is combined with Eslicarbazepine acetate. |
| Eszopiclone | The serum concentration of Eszopiclone can be increased when it is combined with Palbociclib. |
| Ethosuximide | The serum concentration of Ethosuximide can be increased when it is combined with Palbociclib. |
| Etoposide | The serum concentration of Etoposide can be increased when it is combined with Palbociclib. |
| Etravirine | The serum concentration of Palbociclib can be decreased when it is combined with Etravirine. |
| Everolimus | The serum concentration of Everolimus can be increased when it is combined with Palbociclib. |
| Felbamate | The serum concentration of Felbamate can be increased when it is combined with Palbociclib. |
| Felodipine | The serum concentration of Felodipine can be increased when it is combined with Palbociclib. |
| Fentanyl | The serum concentration of Fentanyl can be increased when it is combined with Palbociclib. |
| Fesoterodine | The serum concentration of Fesoterodine can be increased when it is combined with Palbociclib. |
| Flibanserin | The serum concentration of Flibanserin can be increased when it is combined with Palbociclib. |
| Fluconazole | The metabolism of Palbociclib can be decreased when combined with Fluconazole. |
| Flunisolide | The serum concentration of Flunisolide can be increased when it is combined with Palbociclib. |
| Flurazepam | The serum concentration of Flurazepam can be increased when it is combined with Palbociclib. |
| Flutamide | The serum concentration of Flutamide can be increased when it is combined with Palbociclib. |
| Fosaprepitant | The serum concentration of Fosaprepitant can be increased when it is combined with Palbociclib. |
| Fosphenytoin | The serum concentration of Palbociclib can be decreased when it is combined with Fosphenytoin. |
| Fusidic Acid | The serum concentration of Palbociclib can be increased when it is combined with Fusidic Acid. |
| Gefitinib | The serum concentration of Gefitinib can be increased when it is combined with Palbociclib. |
| Guanfacine | The serum concentration of Guanfacine can be increased when it is combined with Palbociclib. |
| Haloperidol | The serum concentration of Haloperidol can be increased when it is combined with Palbociclib. |
| Hydrocodone | The serum concentration of Hydrocodone can be increased when it is combined with Palbociclib. |
| Hydroxyprogesterone caproate | The serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Palbociclib. |
| Ibrutinib | The serum concentration of Ibrutinib can be increased when it is combined with Palbociclib. |
| Idelalisib | The serum concentration of Palbociclib can be increased when it is combined with Idelalisib. |
| Indinavir | The serum concentration of Palbociclib can be increased when it is combined with Indinavir. |
| Irinotecan | The serum concentration of Irinotecan can be increased when it is combined with Palbociclib. |
| Isavuconazonium | The serum concentration of Isavuconazonium can be increased when it is combined with Palbociclib. |
| Isosorbide | The serum concentration of Isosorbide can be increased when it is combined with Palbociclib. |
| Isosorbide Dinitrate | The serum concentration of Isosorbide Dinitrate can be increased when it is combined with Palbociclib. |
| Isosorbide Mononitrate | The serum concentration of Isosorbide Mononitrate can be increased when it is combined with Palbociclib. |
| Isradipine | The serum concentration of Isradipine can be increased when it is combined with Palbociclib. |
| Itraconazole | The serum concentration of Palbociclib can be increased when it is combined with Itraconazole. |
| Ivabradine | The serum concentration of Ivabradine can be increased when it is combined with Palbociclib. |
| Ivacaftor | The serum concentration of Ivacaftor can be increased when it is combined with Palbociclib. |
| Ixabepilone | The serum concentration of Ixabepilone can be increased when it is combined with Palbociclib. |
| Ketamine | The serum concentration of Ketamine can be increased when it is combined with Palbociclib. |
| Ketoconazole | The serum concentration of Palbociclib can be increased when it is combined with Ketoconazole. |
| Lapatinib | The serum concentration of Lapatinib can be increased when it is combined with Palbociclib. |
| Leflunomide | The risk or severity of adverse effects can be increased when Palbociclib is combined with Leflunomide. |
| Levomilnacipran | The serum concentration of Levomilnacipran can be increased when it is combined with Palbociclib. |
| Lidocaine | The serum concentration of Lidocaine can be increased when it is combined with Palbociclib. |
| Lomitapide | The serum concentration of Lomitapide can be increased when it is combined with Palbociclib. |
| Lovastatin | The serum concentration of Lovastatin can be increased when it is combined with Palbociclib. |
| Luliconazole | The serum concentration of Palbociclib can be increased when it is combined with Luliconazole. |
| Lurasidone | The serum concentration of Lurasidone can be increased when it is combined with Palbociclib. |
| MACITENTAN | The serum concentration of MACITENTAN can be increased when it is combined with Palbociclib. |
| Maraviroc | The serum concentration of Maraviroc can be increased when it is combined with Palbociclib. |
| Mefloquine | The serum concentration of Mefloquine can be increased when it is combined with Palbociclib. |
| Metamizole | The risk or severity of adverse effects can be increased when Metamizole is combined with Palbociclib. |
| Methadone | The serum concentration of Methadone can be increased when it is combined with Palbociclib. |
| Midazolam | The serum concentration of Midazolam can be increased when it is combined with Palbociclib. |
| Mifepristone | The serum concentration of Palbociclib can be increased when it is combined with Mifepristone. |
| Mirtazapine | The serum concentration of Mirtazapine can be increased when it is combined with Palbociclib. |
| Mitotane | The serum concentration of Palbociclib can be decreased when it is combined with Mitotane. |
| Modafinil | The serum concentration of Palbociclib can be decreased when it is combined with Modafinil. |
| Nafcillin | The serum concentration of Palbociclib can be decreased when it is combined with Nafcillin. |
| Naloxegol | The serum concentration of Naloxegol can be increased when it is combined with Palbociclib. |
| Natalizumab | The risk or severity of adverse effects can be increased when Palbociclib is combined with Natalizumab. |
| Nateglinide | The serum concentration of Nateglinide can be increased when it is combined with Palbociclib. |
| Nefazodone | The serum concentration of Palbociclib can be increased when it is combined with Nefazodone. |
| Nelfinavir | The serum concentration of Palbociclib can be increased when it is combined with Nelfinavir. |
| Netupitant | The serum concentration of Palbociclib can be increased when it is combined with Netupitant. |
| Nicardipine | The serum concentration of Nicardipine can be increased when it is combined with Palbociclib. |
| Nifedipine | The serum concentration of Nifedipine can be increased when it is combined with Palbociclib. |
| Nilotinib | The serum concentration of Nilotinib can be increased when it is combined with Palbociclib. |
| Nimodipine | The serum concentration of Nimodipine can be increased when it is combined with Palbociclib. |
| Nisoldipine | The serum concentration of Nisoldipine can be increased when it is combined with Palbociclib. |
| Olaparib | The serum concentration of Olaparib can be increased when it is combined with Palbociclib. |
| Oxycodone | The serum concentration of Oxycodone can be increased when it is combined with Palbociclib. |
| Paclitaxel | The serum concentration of Paclitaxel can be increased when it is combined with Palbociclib. |
| Panobinostat | The serum concentration of Panobinostat can be increased when it is combined with Palbociclib. |
| Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Palbociclib. |
| Phenobarbital | The serum concentration of Palbociclib can be decreased when it is combined with Phenobarbital. |
| Phenytoin | The serum concentration of Palbociclib can be decreased when it is combined with Phenytoin. |
| Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Palbociclib. |
| Pimozide | The serum concentration of Pimozide can be increased when it is combined with Palbociclib. |
| Pipotiazine | The serum concentration of Pipotiazine can be increased when it is combined with Palbociclib. |
| Posaconazole | The serum concentration of Palbociclib can be increased when it is combined with Posaconazole. |
| Praziquantel | The serum concentration of Praziquantel can be increased when it is combined with Palbociclib. |
| Primidone | The serum concentration of Palbociclib can be decreased when it is combined with Primidone. |
| Quetiapine | The serum concentration of Quetiapine can be increased when it is combined with Palbociclib. |
| Quinidine | The serum concentration of Quinidine can be increased when it is combined with Palbociclib. |
| Quinine | The serum concentration of Quinine can be increased when it is combined with Palbociclib. |
| Ranolazine | The serum concentration of Ranolazine can be increased when it is combined with Palbociclib. |
| Regorafenib | The serum concentration of Regorafenib can be increased when it is combined with Palbociclib. |
| Rifabutin | The serum concentration of Palbociclib can be decreased when it is combined with Rifabutin. |
| Rifampicin | The serum concentration of Palbociclib can be decreased when it is combined with Rifampicin. |
| Rifapentine | The serum concentration of Palbociclib can be decreased when it is combined with Rifapentine. |
| Ritonavir | The serum concentration of Palbociclib can be increased when it is combined with Ritonavir. |
| Roflumilast | Roflumilast may increase the immunosuppressive activities of Palbociclib. |
| Ruxolitinib | The serum concentration of Ruxolitinib can be increased when it is combined with Palbociclib. |
| Salmeterol | The serum concentration of Salmeterol can be increased when it is combined with Palbociclib. |
| Saquinavir | The serum concentration of Palbociclib can be increased when it is combined with Saquinavir. |
| Saxagliptin | The serum concentration of Saxagliptin can be increased when it is combined with Palbociclib. |
| Sildenafil | The serum concentration of Sildenafil can be increased when it is combined with Palbociclib. |
| Silodosin | The serum concentration of Silodosin can be increased when it is combined with Palbociclib. |
| Siltuximab | The serum concentration of Palbociclib can be decreased when it is combined with Siltuximab. |
| Simeprevir | The serum concentration of Simeprevir can be increased when it is combined with Palbociclib. |
| Simvastatin | The serum concentration of Simvastatin can be increased when it is combined with Palbociclib. |
| Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Palbociclib. |
| Sirolimus | The serum concentration of Sirolimus can be increased when it is combined with Palbociclib. |
| Solifenacin | The serum concentration of Solifenacin can be increased when it is combined with Palbociclib. |
| Sonidegib | The serum concentration of Sonidegib can be increased when it is combined with Palbociclib. |
| Spiramycin | The serum concentration of Spiramycin can be increased when it is combined with Palbociclib. |
| Stiripentol | The serum concentration of Palbociclib can be increased when it is combined with Stiripentol. |
| Sufentanil | The serum concentration of Sufentanil can be increased when it is combined with Palbociclib. |
| Sunitinib | The serum concentration of Sunitinib can be increased when it is combined with Palbociclib. |
| Suvorexant | The serum concentration of Suvorexant can be increased when it is combined with Palbociclib. |
| Tacrolimus | The serum concentration of Tacrolimus can be increased when it is combined with Palbociclib. |
| Tadalafil | The serum concentration of Tadalafil can be increased when it is combined with Palbociclib. |
| Tamoxifen | The serum concentration of Tamoxifen can be increased when it is combined with Palbociclib. |
| Tamsulosin | The serum concentration of Tamsulosin can be increased when it is combined with Palbociclib. |
| Telaprevir | The serum concentration of Palbociclib can be increased when it is combined with Telaprevir. |
| Telithromycin | The serum concentration of Palbociclib can be increased when it is combined with Telithromycin. |
| Temsirolimus | The serum concentration of Temsirolimus can be increased when it is combined with Palbociclib. |
| Teniposide | The serum concentration of Teniposide can be increased when it is combined with Palbociclib. |
| Theophylline | The serum concentration of Theophylline can be increased when it is combined with Palbociclib. |
| Tiagabine | The serum concentration of Tiagabine can be increased when it is combined with Palbociclib. |
| Tocilizumab | The serum concentration of Palbociclib can be decreased when it is combined with Tocilizumab. |
| Tofacitinib | Palbociclib may increase the immunosuppressive activities of Tofacitinib. |
| Tolterodine | The serum concentration of Tolterodine can be increased when it is combined with Palbociclib. |
| Tolvaptan | The serum concentration of Tolvaptan can be increased when it is combined with Palbociclib. |
| Trabectedin | The serum concentration of Trabectedin can be increased when it is combined with Palbociclib. |
| Trastuzumab | Trastuzumab may increase the neutropenic activities of Palbociclib. |
| Trazodone | The serum concentration of Trazodone can be increased when it is combined with Palbociclib. |
| Triazolam | The serum concentration of Triazolam can be increased when it is combined with Palbociclib. |
| Trimipramine | The serum concentration of Trimipramine can be increased when it is combined with Palbociclib. |
| Vardenafil | The serum concentration of Vardenafil can be increased when it is combined with Palbociclib. |
| Vemurafenib | The serum concentration of Vemurafenib can be increased when it is combined with Palbociclib. |
| Venlafaxine | The serum concentration of Venlafaxine can be increased when it is combined with Palbociclib. |
| Verapamil | The serum concentration of Verapamil can be increased when it is combined with Palbociclib. |
| Vinblastine | The serum concentration of Vinblastine can be increased when it is combined with Palbociclib. |
| Vincristine | The serum concentration of Vincristine can be increased when it is combined with Palbociclib. |
| Vinorelbine | The serum concentration of Vinorelbine can be increased when it is combined with Palbociclib. |
| Voriconazole | The serum concentration of Palbociclib can be increased when it is combined with Voriconazole. |
| Zolpidem | The serum concentration of Zolpidem can be increased when it is combined with Palbociclib. |
| Zonisamide | The serum concentration of Zonisamide can be increased when it is combined with Palbociclib. |
| Zopiclone | The serum concentration of Zopiclone can be increased when it is combined with Palbociclib. |
| Drug | Interaction |
|---|---|
| ado-trastuzumab emtansine | The serum concentration of ado-trastuzumab emtansine can be increased when it is combined with Palbociclib. |
| Alfentanil | The serum concentration of Alfentanil can be increased when it is combined with Palbociclib. |
| Alfuzosin | The serum concentration of Alfuzosin can be increased when it is combined with Palbociclib. |
| Alitretinoin | The serum concentration of Alitretinoin can be increased when it is combined with Palbociclib. |
| Alprazolam | The serum concentration of Alprazolam can be increased when it is combined with Palbociclib. |
| Aminophylline | The serum concentration of Aminophylline can be increased when it is combined with Palbociclib. |
| Amiodarone | The serum concentration of Amiodarone can be increased when it is combined with Palbociclib. |
| Amlodipine | The serum concentration of Amlodipine can be increased when it is combined with Palbociclib. |
| Aprepitant | The serum concentration of Aprepitant can be increased when it is combined with Palbociclib. |
| Aripiprazole | The serum concentration of Aripiprazole can be increased when it is combined with Palbociclib. |
| Armodafinil | The serum concentration of Armodafinil can be increased when it is combined with Palbociclib. |
| Atazanavir | The serum concentration of Palbociclib can be increased when it is combined with Atazanavir. |
| Atorvastatin | The serum concentration of Atorvastatin can be increased when it is combined with Palbociclib. |
| Avanafil | The serum concentration of Avanafil can be increased when it is combined with Palbociclib. |
| Axitinib | The serum concentration of Axitinib can be increased when it is combined with Palbociclib. |
| Benzphetamine | The serum concentration of Benzphetamine can be increased when it is combined with Palbociclib. |
| Bexarotene | The serum concentration of Palbociclib can be decreased when it is combined with Bexarotene. |
| Bisoprolol | The serum concentration of Bisoprolol can be increased when it is combined with Palbociclib. |
| Boceprevir | The serum concentration of Palbociclib can be increased when it is combined with Boceprevir. |
| Bosentan | The serum concentration of Palbociclib can be decreased when it is combined with Bosentan. |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Palbociclib. |
| Brexpiprazole | The serum concentration of Brexpiprazole can be increased when it is combined with Palbociclib. |
| Bromocriptine | The serum concentration of Bromocriptine can be increased when it is combined with Palbociclib. |
| Budesonide | The serum concentration of Budesonide can be increased when it is combined with Palbociclib. |
| Buprenorphine | The serum concentration of Buprenorphine can be increased when it is combined with Palbociclib. |
| Buspirone | The serum concentration of Buspirone can be increased when it is combined with Palbociclib. |
| Cabazitaxel | The serum concentration of Cabazitaxel can be increased when it is combined with Palbociclib. |
| Cabozantinib | The serum concentration of Cabozantinib can be increased when it is combined with Palbociclib. |
| Calcitriol | The serum concentration of Calcitriol can be increased when it is combined with Palbociclib. |
| Carbamazepine | The serum concentration of Palbociclib can be decreased when it is combined with Carbamazepine. |
| Ceritinib | The serum concentration of Palbociclib can be increased when it is combined with Ceritinib. |
| Chlordiazepoxide | The serum concentration of Chlordiazepoxide can be increased when it is combined with Palbociclib. |
| Chloroquine | The serum concentration of Chloroquine can be increased when it is combined with Palbociclib. |
| Cilostazol | The serum concentration of Cilostazol can be increased when it is combined with Palbociclib. |
| Cinacalcet | The serum concentration of Cinacalcet can be increased when it is combined with Palbociclib. |
| Cisapride | The serum concentration of Cisapride can be increased when it is combined with Palbociclib. |
| Citalopram | The serum concentration of Citalopram can be increased when it is combined with Palbociclib. |
| Clarithromycin | The serum concentration of Palbociclib can be increased when it is combined with Clarithromycin. |
| Clonazepam | The serum concentration of Clonazepam can be increased when it is combined with Palbociclib. |
| Clorazepate | The serum concentration of Clorazepate can be increased when it is combined with Palbociclib. |
| Clozapine | The risk or severity of adverse effects can be increased when Palbociclib is combined with Clozapine. |
| Cobicistat | The serum concentration of Palbociclib can be increased when it is combined with Cobicistat. |
| Cobimetinib | The serum concentration of Cobimetinib can be increased when it is combined with Palbociclib. |
| Cocaine | The serum concentration of Cocaine can be increased when it is combined with Palbociclib. |
| Colchicine | The serum concentration of Colchicine can be increased when it is combined with Palbociclib. |
| Conivaptan | The serum concentration of Palbociclib can be increased when it is combined with Conivaptan. |
| Crizotinib | The serum concentration of Crizotinib can be increased when it is combined with Palbociclib. |
| Cyclosporine | The serum concentration of Cyclosporine can be increased when it is combined with Palbociclib. |
| Cyproterone acetate | The serum concentration of Cyproterone acetate can be increased when it is combined with Palbociclib. |
| Dabrafenib | The serum concentration of Palbociclib can be decreased when it is combined with Dabrafenib. |
| Daclatasvir | The serum concentration of Daclatasvir can be increased when it is combined with Palbociclib. |
| Dantrolene | The serum concentration of Dantrolene can be increased when it is combined with Palbociclib. |
| Dapsone | The serum concentration of Dapsone can be increased when it is combined with Palbociclib. |
| Darifenacin | The serum concentration of Darifenacin can be increased when it is combined with Palbociclib. |
| Darunavir | The serum concentration of Palbociclib can be increased when it is combined with Darunavir. |
| Dasatinib | The serum concentration of Dasatinib can be increased when it is combined with Palbociclib. |
| Deferasirox | The serum concentration of Palbociclib can be decreased when it is combined with Deferasirox. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Palbociclib. |
| Dexamethasone | The serum concentration of Palbociclib can be decreased when it is combined with Dexamethasone. |
| Diazepam | The serum concentration of Diazepam can be increased when it is combined with Palbociclib. |
| Dihydroergotamine | The serum concentration of Dihydroergotamine can be increased when it is combined with Palbociclib. |
| Diltiazem | The serum concentration of Diltiazem can be increased when it is combined with Palbociclib. |
| Disopyramide | The serum concentration of Disopyramide can be increased when it is combined with Palbociclib. |
| Docetaxel | The serum concentration of Docetaxel can be increased when it is combined with Palbociclib. |
| Dofetilide | The serum concentration of Dofetilide can be increased when it is combined with Palbociclib. |
| Domperidone | The serum concentration of Domperidone can be increased when it is combined with Palbociclib. |
| Doxazosin | The serum concentration of Doxazosin can be increased when it is combined with Palbociclib. |
| Doxorubicin | The serum concentration of Doxorubicin can be increased when it is combined with Palbociclib. |
| Dronedarone | The serum concentration of Dronedarone can be increased when it is combined with Palbociclib. |
| Efavirenz | The serum concentration of Palbociclib can be decreased when it is combined with Efavirenz. |
| Eletriptan | The serum concentration of Eletriptan can be increased when it is combined with Palbociclib. |
| Eliglustat | The serum concentration of Eliglustat can be increased when it is combined with Palbociclib. |
| Enzalutamide | The serum concentration of Palbociclib can be decreased when it is combined with Enzalutamide. |
| Eplerenone | The serum concentration of Eplerenone can be increased when it is combined with Palbociclib. |
| Ergoloid mesylate | The serum concentration of Ergoloid mesylate can be increased when it is combined with Palbociclib. |
| Ergonovine | The serum concentration of Ergonovine can be increased when it is combined with Palbociclib. |
| Ergotamine | The serum concentration of Ergotamine can be increased when it is combined with Palbociclib. |
| Erlotinib | The serum concentration of Erlotinib can be increased when it is combined with Palbociclib. |
| Erythromycin | The serum concentration of Erythromycin can be increased when it is combined with Palbociclib. |
| Escitalopram | The serum concentration of Escitalopram can be increased when it is combined with Palbociclib. |
| Eslicarbazepine acetate | The serum concentration of Palbociclib can be decreased when it is combined with Eslicarbazepine acetate. |
| Eszopiclone | The serum concentration of Eszopiclone can be increased when it is combined with Palbociclib. |
| Ethosuximide | The serum concentration of Ethosuximide can be increased when it is combined with Palbociclib. |
| Etoposide | The serum concentration of Etoposide can be increased when it is combined with Palbociclib. |
| Etravirine | The serum concentration of Palbociclib can be decreased when it is combined with Etravirine. |
| Everolimus | The serum concentration of Everolimus can be increased when it is combined with Palbociclib. |
| Felbamate | The serum concentration of Felbamate can be increased when it is combined with Palbociclib. |
| Felodipine | The serum concentration of Felodipine can be increased when it is combined with Palbociclib. |
| Fentanyl | The serum concentration of Fentanyl can be increased when it is combined with Palbociclib. |
| Fesoterodine | The serum concentration of Fesoterodine can be increased when it is combined with Palbociclib. |
| Flibanserin | The serum concentration of Flibanserin can be increased when it is combined with Palbociclib. |
| Fluconazole | The metabolism of Palbociclib can be decreased when combined with Fluconazole. |
| Flunisolide | The serum concentration of Flunisolide can be increased when it is combined with Palbociclib. |
| Flurazepam | The serum concentration of Flurazepam can be increased when it is combined with Palbociclib. |
| Flutamide | The serum concentration of Flutamide can be increased when it is combined with Palbociclib. |
| Fosaprepitant | The serum concentration of Fosaprepitant can be increased when it is combined with Palbociclib. |
| Fosphenytoin | The serum concentration of Palbociclib can be decreased when it is combined with Fosphenytoin. |
| Fusidic Acid | The serum concentration of Palbociclib can be increased when it is combined with Fusidic Acid. |
| Gefitinib | The serum concentration of Gefitinib can be increased when it is combined with Palbociclib. |
| Guanfacine | The serum concentration of Guanfacine can be increased when it is combined with Palbociclib. |
| Haloperidol | The serum concentration of Haloperidol can be increased when it is combined with Palbociclib. |
| Hydrocodone | The serum concentration of Hydrocodone can be increased when it is combined with Palbociclib. |
| Hydroxyprogesterone caproate | The serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Palbociclib. |
| Ibrutinib | The serum concentration of Ibrutinib can be increased when it is combined with Palbociclib. |
| Idelalisib | The serum concentration of Palbociclib can be increased when it is combined with Idelalisib. |
| Indinavir | The serum concentration of Palbociclib can be increased when it is combined with Indinavir. |
| Irinotecan | The serum concentration of Irinotecan can be increased when it is combined with Palbociclib. |
| Isavuconazonium | The serum concentration of Isavuconazonium can be increased when it is combined with Palbociclib. |
| Isosorbide | The serum concentration of Isosorbide can be increased when it is combined with Palbociclib. |
| Isosorbide Dinitrate | The serum concentration of Isosorbide Dinitrate can be increased when it is combined with Palbociclib. |
| Isosorbide Mononitrate | The serum concentration of Isosorbide Mononitrate can be increased when it is combined with Palbociclib. |
| Isradipine | The serum concentration of Isradipine can be increased when it is combined with Palbociclib. |
| Itraconazole | The serum concentration of Palbociclib can be increased when it is combined with Itraconazole. |
| Ivabradine | The serum concentration of Ivabradine can be increased when it is combined with Palbociclib. |
| Ivacaftor | The serum concentration of Ivacaftor can be increased when it is combined with Palbociclib. |
| Ixabepilone | The serum concentration of Ixabepilone can be increased when it is combined with Palbociclib. |
| Ketamine | The serum concentration of Ketamine can be increased when it is combined with Palbociclib. |
| Ketoconazole | The serum concentration of Palbociclib can be increased when it is combined with Ketoconazole. |
| Lapatinib | The serum concentration of Lapatinib can be increased when it is combined with Palbociclib. |
| Leflunomide | The risk or severity of adverse effects can be increased when Palbociclib is combined with Leflunomide. |
| Levomilnacipran | The serum concentration of Levomilnacipran can be increased when it is combined with Palbociclib. |
| Lidocaine | The serum concentration of Lidocaine can be increased when it is combined with Palbociclib. |
| Lomitapide | The serum concentration of Lomitapide can be increased when it is combined with Palbociclib. |
| Lovastatin | The serum concentration of Lovastatin can be increased when it is combined with Palbociclib. |
| Luliconazole | The serum concentration of Palbociclib can be increased when it is combined with Luliconazole. |
| Lurasidone | The serum concentration of Lurasidone can be increased when it is combined with Palbociclib. |
| MACITENTAN | The serum concentration of MACITENTAN can be increased when it is combined with Palbociclib. |
| Maraviroc | The serum concentration of Maraviroc can be increased when it is combined with Palbociclib. |
| Mefloquine | The serum concentration of Mefloquine can be increased when it is combined with Palbociclib. |
| Metamizole | The risk or severity of adverse effects can be increased when Metamizole is combined with Palbociclib. |
| Methadone | The serum concentration of Methadone can be increased when it is combined with Palbociclib. |
| Midazolam | The serum concentration of Midazolam can be increased when it is combined with Palbociclib. |
| Mifepristone | The serum concentration of Palbociclib can be increased when it is combined with Mifepristone. |
| Mirtazapine | The serum concentration of Mirtazapine can be increased when it is combined with Palbociclib. |
| Mitotane | The serum concentration of Palbociclib can be decreased when it is combined with Mitotane. |
| Modafinil | The serum concentration of Palbociclib can be decreased when it is combined with Modafinil. |
| Nafcillin | The serum concentration of Palbociclib can be decreased when it is combined with Nafcillin. |
| Naloxegol | The serum concentration of Naloxegol can be increased when it is combined with Palbociclib. |
| Natalizumab | The risk or severity of adverse effects can be increased when Palbociclib is combined with Natalizumab. |
| Nateglinide | The serum concentration of Nateglinide can be increased when it is combined with Palbociclib. |
| Nefazodone | The serum concentration of Palbociclib can be increased when it is combined with Nefazodone. |
| Nelfinavir | The serum concentration of Palbociclib can be increased when it is combined with Nelfinavir. |
| Netupitant | The serum concentration of Palbociclib can be increased when it is combined with Netupitant. |
| Nicardipine | The serum concentration of Nicardipine can be increased when it is combined with Palbociclib. |
| Nifedipine | The serum concentration of Nifedipine can be increased when it is combined with Palbociclib. |
| Nilotinib | The serum concentration of Nilotinib can be increased when it is combined with Palbociclib. |
| Nimodipine | The serum concentration of Nimodipine can be increased when it is combined with Palbociclib. |
| Nisoldipine | The serum concentration of Nisoldipine can be increased when it is combined with Palbociclib. |
| Olaparib | The serum concentration of Olaparib can be increased when it is combined with Palbociclib. |
| Oxycodone | The serum concentration of Oxycodone can be increased when it is combined with Palbociclib. |
| Paclitaxel | The serum concentration of Paclitaxel can be increased when it is combined with Palbociclib. |
| Panobinostat | The serum concentration of Panobinostat can be increased when it is combined with Palbociclib. |
| Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Palbociclib. |
| Phenobarbital | The serum concentration of Palbociclib can be decreased when it is combined with Phenobarbital. |
| Phenytoin | The serum concentration of Palbociclib can be decreased when it is combined with Phenytoin. |
| Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Palbociclib. |
| Pimozide | The serum concentration of Pimozide can be increased when it is combined with Palbociclib. |
| Pipotiazine | The serum concentration of Pipotiazine can be increased when it is combined with Palbociclib. |
| Posaconazole | The serum concentration of Palbociclib can be increased when it is combined with Posaconazole. |
| Praziquantel | The serum concentration of Praziquantel can be increased when it is combined with Palbociclib. |
| Primidone | The serum concentration of Palbociclib can be decreased when it is combined with Primidone. |
| Quetiapine | The serum concentration of Quetiapine can be increased when it is combined with Palbociclib. |
| Quinidine | The serum concentration of Quinidine can be increased when it is combined with Palbociclib. |
| Quinine | The serum concentration of Quinine can be increased when it is combined with Palbociclib. |
| Ranolazine | The serum concentration of Ranolazine can be increased when it is combined with Palbociclib. |
| Regorafenib | The serum concentration of Regorafenib can be increased when it is combined with Palbociclib. |
| Rifabutin | The serum concentration of Palbociclib can be decreased when it is combined with Rifabutin. |
| Rifampicin | The serum concentration of Palbociclib can be decreased when it is combined with Rifampicin. |
| Rifapentine | The serum concentration of Palbociclib can be decreased when it is combined with Rifapentine. |
| Ritonavir | The serum concentration of Palbociclib can be increased when it is combined with Ritonavir. |
| Roflumilast | Roflumilast may increase the immunosuppressive activities of Palbociclib. |
| Ruxolitinib | The serum concentration of Ruxolitinib can be increased when it is combined with Palbociclib. |
| Salmeterol | The serum concentration of Salmeterol can be increased when it is combined with Palbociclib. |
| Saquinavir | The serum concentration of Palbociclib can be increased when it is combined with Saquinavir. |
| Saxagliptin | The serum concentration of Saxagliptin can be increased when it is combined with Palbociclib. |
| Sildenafil | The serum concentration of Sildenafil can be increased when it is combined with Palbociclib. |
| Silodosin | The serum concentration of Silodosin can be increased when it is combined with Palbociclib. |
| Siltuximab | The serum concentration of Palbociclib can be decreased when it is combined with Siltuximab. |
| Simeprevir | The serum concentration of Simeprevir can be increased when it is combined with Palbociclib. |
| Simvastatin | The serum concentration of Simvastatin can be increased when it is combined with Palbociclib. |
| Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Palbociclib. |
| Sirolimus | The serum concentration of Sirolimus can be increased when it is combined with Palbociclib. |
| Solifenacin | The serum concentration of Solifenacin can be increased when it is combined with Palbociclib. |
| Sonidegib | The serum concentration of Sonidegib can be increased when it is combined with Palbociclib. |
| Spiramycin | The serum concentration of Spiramycin can be increased when it is combined with Palbociclib. |
| Stiripentol | The serum concentration of Palbociclib can be increased when it is combined with Stiripentol. |
| Sufentanil | The serum concentration of Sufentanil can be increased when it is combined with Palbociclib. |
| Sunitinib | The serum concentration of Sunitinib can be increased when it is combined with Palbociclib. |
| Suvorexant | The serum concentration of Suvorexant can be increased when it is combined with Palbociclib. |
| Tacrolimus | The serum concentration of Tacrolimus can be increased when it is combined with Palbociclib. |
| Tadalafil | The serum concentration of Tadalafil can be increased when it is combined with Palbociclib. |
| Tamoxifen | The serum concentration of Tamoxifen can be increased when it is combined with Palbociclib. |
| Tamsulosin | The serum concentration of Tamsulosin can be increased when it is combined with Palbociclib. |
| Telaprevir | The serum concentration of Palbociclib can be increased when it is combined with Telaprevir. |
| Telithromycin | The serum concentration of Palbociclib can be increased when it is combined with Telithromycin. |
| Temsirolimus | The serum concentration of Temsirolimus can be increased when it is combined with Palbociclib. |
| Teniposide | The serum concentration of Teniposide can be increased when it is combined with Palbociclib. |
| Theophylline | The serum concentration of Theophylline can be increased when it is combined with Palbociclib. |
| Tiagabine | The serum concentration of Tiagabine can be increased when it is combined with Palbociclib. |
| Tocilizumab | The serum concentration of Palbociclib can be decreased when it is combined with Tocilizumab. |
| Tofacitinib | Palbociclib may increase the immunosuppressive activities of Tofacitinib. |
| Tolterodine | The serum concentration of Tolterodine can be increased when it is combined with Palbociclib. |
| Tolvaptan | The serum concentration of Tolvaptan can be increased when it is combined with Palbociclib. |
| Trabectedin | The serum concentration of Trabectedin can be increased when it is combined with Palbociclib. |
| Trastuzumab | Trastuzumab may increase the neutropenic activities of Palbociclib. |
| Trazodone | The serum concentration of Trazodone can be increased when it is combined with Palbociclib. |
| Triazolam | The serum concentration of Triazolam can be increased when it is combined with Palbociclib. |
| Trimipramine | The serum concentration of Trimipramine can be increased when it is combined with Palbociclib. |
| Vardenafil | The serum concentration of Vardenafil can be increased when it is combined with Palbociclib. |
| Vemurafenib | The serum concentration of Vemurafenib can be increased when it is combined with Palbociclib. |
| Venlafaxine | The serum concentration of Venlafaxine can be increased when it is combined with Palbociclib. |
| Verapamil | The serum concentration of Verapamil can be increased when it is combined with Palbociclib. |
| Vinblastine | The serum concentration of Vinblastine can be increased when it is combined with Palbociclib. |
| Vincristine | The serum concentration of Vincristine can be increased when it is combined with Palbociclib. |
| Vinorelbine | The serum concentration of Vinorelbine can be increased when it is combined with Palbociclib. |
| Voriconazole | The serum concentration of Palbociclib can be increased when it is combined with Voriconazole. |
| Zolpidem | The serum concentration of Zolpidem can be increased when it is combined with Palbociclib. |
| Zonisamide | The serum concentration of Zonisamide can be increased when it is combined with Palbociclib. |
| Zopiclone | The serum concentration of Zopiclone can be increased when it is combined with Palbociclib. |
Food Interactions:
- Not Available
Taxonomy
Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
substituent:
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- Aminopyridines and derivatives
- Aryl alkyl ketones
- Azacyclic compounds
- Dialkylamines
- Dialkylarylamines
- Heteroaromatic compounds
- Hydrocarbon derivatives
- Imidolactams
- Lactams
- Methylpyridines
- N-arylpiperazines
- Pyridinones
- Pyridopyrimidines
- Pyrimidines and pyrimidine derivatives
- Vinylogous amides
substituent:
- Amine
- Aminopyridine
- Aromatic heteropolycyclic compound
- Aryl alkyl ketone
- Aryl ketone
- Azacycle
- Carbonyl group
- Dialkylarylamine
- Heteroaromatic compound
- Hydrocarbon derivative
- Imidolactam
- Ketone
- Lactam
- Methylpyridine
- N-arylpiperazine
- Organonitrogen compound
- Organooxygen compound
- Pyridine
- Pyridinone
- Pyridinylpiperazine
- Pyridopyrimidine
- Pyrimidine
- Secondary aliphatic amine
- Secondary amine
- Tertiary amine
- Vinylogous amide
References
Synthesis Reference: Not Available
General Reference: # Dhillon S: Palbociclib: first global approval. Drugs. 2015 Apr;75(5):543-51. doi: 10.1007/s40265-015-0379-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/25792301 # Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15542782 # Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF: PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 2013 Aug;33(8):2997-3004. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23898052 # Palbociclib Extends Survival in Advanced Breast Cancer. Cancer Discov. 2015 Jun 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/26036642 # Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M: Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jun 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/26030518 # Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/25524798 # DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, Rosen M, Fox K, O'Dwyer P: CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015 Mar 1;21(5):995-1001. doi: 10.1158/1078-0432.CCR-14-2258. Epub 2014 Dec 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/25501126
External Links:
ATC Codes:
AHFS Codes:
MSDS: Download
General Reference: # Dhillon S: Palbociclib: first global approval. Drugs. 2015 Apr;75(5):543-51. doi: 10.1007/s40265-015-0379-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/25792301 # Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15542782 # Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF: PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 2013 Aug;33(8):2997-3004. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23898052 # Palbociclib Extends Survival in Advanced Breast Cancer. Cancer Discov. 2015 Jun 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/26036642 # Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M: Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jun 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/26030518 # Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/25524798 # DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, Rosen M, Fox K, O'Dwyer P: CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015 Mar 1;21(5):995-1001. doi: 10.1158/1078-0432.CCR-14-2258. Epub 2014 Dec 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/25501126
External Links:
| Resource | Link |
|---|---|
| RxList | http://www.rxlist.com/ibrance-drug.htm |
| Drugs.com | http://www.drugs.com/cdi/palbociclib.html |
| Resource | Link |
|---|---|
| RxList | http://www.rxlist.com/ibrance-drug.htm |
| Drugs.com | http://www.drugs.com/cdi/palbociclib.html |
ATC Codes:
- Not Available
AHFS Codes:
- 10:00
MSDS: Download